Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rani Therapeutics Holdings, Inc. RANI
$3.78
-$0.13 (-3.57%)
На 18:04, 12 мая 2023
+640.74%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
221948307.00000000
-
week52high
13.44
-
week52low
3.65
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 20:30
Описание компании
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 27 июл 2022 г. | |
| Wedbush | Outperform | 13 июн 2022 г. | |
| BTIG | Buy | 25 авг 2021 г. | |
| Stifel | Buy | 24 авг 2021 г. | |
| Cantor Fitzgerald | Overweight | 24 авг 2021 г. | |
| UBS | Buy | 11 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| South Cone Investments Limited Partnership | A | 6714654 | 8600 | 30 дек 2022 г. |
| Quiroga Cortes Isidoro Alfonso | A | 5271378 | 8400 | 30 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6706054 | 8600 | 29 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6697454 | 9157 | 28 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6688297 | 6900 | 19 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6681397 | 6400 | 16 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6674997 | 6500 | 15 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6668497 | 7027 | 14 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6658678 | 12050 | 13 дек 2022 г. |
| South Cone Investments Limited Partnership | A | 6646628 | 12500 | 12 дек 2022 г. |
Новостная лента
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rani Therapeutics to Present at the Stifel Healthcare Conference
GlobeNewsWire
09 ноя 2022 г. в 16:05
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022.
Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 16:05
SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person.
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
10 авг 2022 г. в 18:48
Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rani Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire
03 мая 2022 г. в 16:05
SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company's Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May: